Evidence map›Paper›PMID 40605281›Full record

ArticleArchiv der Pharmazie2025

Combining Cyclic Triimidazo Triazine Core With Ethynyl-N-Methyl-Pyridinium Groups for Targeting G-Quadruplex Structures.

Chiara Platella, Stefano Di Ciolo, Andrea Criscuolo, Daniele Malpicci, Rosa Gaglione, Angela Arciello, Domenica Musumeci, Elena Lucenti, Elena Cariati, Daniela Montesarchio and 1 more

Abstract read
In one paragraph

Article in Archiv der Pharmazie, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Chiara PlatellaDepartment of Chemical Sciences, University of Naples Federico II, Napoli, Italy.
Stefano Di CioloDepartment of Chemistry, University of Milan, Milano, Italy.
Andrea CriscuoloDepartment of Chemical Sciences, University of Naples Federico II, Napoli, Italy.
Daniele MalpicciDepartment of Chemistry, University of Milan, Milano, Italy.
Rosa GaglioneDepartment of Chemical Sciences, University of Naples Federico II, Napoli, Italy.
Angela ArcielloDepartment of Chemical Sciences, University of Naples Federico II, Napoli, Italy.
Domenica MusumeciDepartment of Chemical Sciences, University of Naples Federico II, Napoli, Italy.
Elena LucentiInstitute of Chemical Sciences and Technologies "Giulio Natta" (SCITEC) of CNR, Milano, Italy.
Elena CariatiDepartment of Chemistry, University of Milan, Milano, Italy.
Daniela MontesarchioDepartment of Chemical Sciences, University of Naples Federico II, Napoli, Italy.ORCID https://orcid.org/0000-0001-6295-6911
Clelia GianniniDepartment of Chemistry, University of Milan, Milano, Italy.

Funding

The research leading to these results has received funding from: (i) Fondazione AIRC under IG 2020-ID.25046- P.I. Montesarchio Daniela; (ii) CN00000041 National Center for Gene Therapy and Drugs based on RNA Technology and the European Union-NextGeneration EU - P.I. Montesarchio Daniela; (iii) Federico II University, FRA2022 project (CUP: E65F22000050001) - P.I. Musumeci DomenicaThis study is supported by Università degli Studi di Milano: PSR2022_DIP_005_PI_CGIAN.
6 · The paper itself

Abstract

The synthesis and characterization of a mini-library of cyclic triimidazo triazine (TT) derivatives functionalized with one, two, or three ethynyl-N-methyl-pyridinium moieties are reported here. These compounds were designed with the aim of targeting cancer-related DNA G-quadruplex structures. The newly synthesized compounds were tested for their ability to bind G-quadruplexes from both telomeric and oncogene promoter sequences using an affinity chromatography-based assay, spectroscopic and electrophoretic techniques, as well as molecular docking analysis. The obtained results demonstrated the effective capacity of the investigated compounds to specifically recognize the selected G-quadruplex models, with their TT cores targeting the outer G-quartets and their positively charged N-methyl-pyridinium groups interacting with the top edge of G-quadruplex grooves. Notably, the trisubstituted cyclic triimidazole compounds showed higher stabilizing properties than the related disubstituted derivatives, which in turn were stronger binders than their monosubstituted analogs. However, the mono- and disubstituted derivatives showed higher G-quadruplex versus duplex recognition selectivity compared with the trisubstituted ones. Altogether, the biophysical experiments, also in agreement with the biological assays, underlined the advantage of introducing an alkyne linker between the triimidazole core and the methylpyridinium group, proving to be beneficial to increase both the stabilizing effects on the G-quadruplexes and the anticancer activity compared with the analogs of the same family lacking the alkyne linker.

Indexed as

Antineoplastic AgentsG-QuadruplexesPyridinium CompoundsTriazinesHumansMolecular Docking SimulationMolecular StructureStructure-Activity RelationshipAntineoplastic AgentsPyridinium CompoundsTriazinesantiproliferative activitybiophysical characterizationchemical synthesiscyclic triimidazo triazine derivativesG‐quadruplex ligands

Identifiers

PMID40605281
PMCPMC12223358

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.